Panitumumab, cetuximab, and bevacizumab among metastatic colorectal cancer patients with wild-type RAS or BRAF

Trial Profile

Panitumumab, cetuximab, and bevacizumab among metastatic colorectal cancer patients with wild-type RAS or BRAF

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Panitumumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium
    • 05 Aug 2016 New trial record
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top